Document:

EX-10.2

 Exhibit 10.2 

FIRST AMENDMENT TO 

SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT 

THIS FIRST AMENDMENT TO SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered
into this 26th day of June, 2019, by and between SILICON VALLEY BANK, a California corporation (“Bank”) and 10X GENOMICS, INC., a Delaware corporation (“Borrower”). 

RECITALS 

A.    Bank and Borrower have entered into that certain Second Amended and Restated Loan and Security Agreement dated as of
February 9, 2018 (as the same may from time to time be further amended, modified, supplemented or restated, the “Loan Agreement”). 

B.    Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement. 

C.    Borrower has requested that Bank amend the Loan Agreement to (i) extend the Term Loan Amortization Date and the
Tranche B Draw Period and (ii) make certain other revisions to the Loan Agreement as more fully set forth herein. 

D.    Bank has agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the
terms, subject to the conditions and in reliance upon the representations and warranties set forth below. 
 AGREEMENT

 NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable
consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: 

1.    Definitions. Capitalized terms used but not defined in this Amendment, including its preamble and
recitals, shall have the meanings given to them in the Loan Agreement. 
 2.    Amendments to Loan Agreement.

 2.1    Section 6.2 (Financial Statements, Reports, Certificates). 

(a)    Section 6.2 of the Loan Agreement is hereby amended by deleting Sections 6.2(a) through 6.2(d) and
Section 6.2(f) in their entirety and replacing them with the following: 
 (a)    a Borrowing Base
Report (and any schedules related thereto and including any other information reasonably requested by Bank with respect to Borrower’s Accounts) (i) upon each request for an Advance, (ii) within thirty (30) days after the last day
of each month, and (iii) at Bank’s option in its sole discretion while there are outstanding Advances, within five (5) days after the last day of each week; provided  

 
however, the reporting in clause (ii) of this Section 6.2(a) shall not be required if there were no Advances outstanding during such period through and including the date that
the reporting would otherwise be required to be delivered; 
 (b)    within thirty (30) days after
the last day of each month, (i) monthly accounts receivable agings, aged by invoice date, (ii) monthly accounts payable agings, aged by invoice date, and outstanding or held check registers, if any, and (iii) monthly reconciliations
of accounts receivable agings (aged by invoice date), transaction reports, and general ledger; provided however, the reporting in this Section 6.2(b) shall not be required if there were no Advances outstanding during such period through
and including the date that the reporting would otherwise be required to be delivered; 
 (c)    as soon
as available, but no later than thirty (30) days after the last day of each month (but upon the occurrence of an IPO and at all times thereafter, not later than forty-five (45) days after the last day of each fiscal quarter of the first
three (3) quarters of Borrower’s fiscal year and not later than ninety (90) days after the last day of Borrower’s fiscal year), a company-prepared consolidated balance sheet and income statement (including, without limitation, a
profit and loss statement) covering Borrower’s consolidated operations for such month if no IPO has occurred and for such quarter upon the occurrence of an IPO and at all times thereafter, certified by a Responsible Officer and in a form
acceptable to Bank in its reasonable discretion (the “Period-Ending Financial Statements”); 

(d)    within thirty (30) days after the last day of each month and together with the applicable
Period-Ending Financial Statements, a duly completed Compliance Certificate signed by a Responsible Officer, certifying that as of the end of such month, Borrower was in full compliance with all of the terms and conditions of this Agreement, and
setting forth calculations showing compliance with the financial covenants set forth in this Agreement and such other information as Bank may reasonably request; provided that, upon the occurrence of an IPO and at all times thereafter, such
Compliance Certificate shall be delivered within (i) forty-five (45) days after the last day of each fiscal quarter of the first three (3) quarters of Borrower’s fiscal year and together with the applicable Period-Ending
Financial Statements, and (ii) the earlier of (x) ninety (90) days after the last day of Borrower’s fiscal year and together with the applicable Period-Ending Financial Statements, or (y) five (5) days after Borrower files any 10-K with the SEC; 
 (f)    as soon as available, and in any event
within two hundred seventy (270) days after the last day of Borrower’s fiscal year, audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion (other than a qualification as to
going concern typical for venture backed companies similar to Borrower) on the financial statements from an independent certified public accounting firm reasonably acceptable to Bank (“Audited Financial Statements”); provided,
however, for any fiscal year for which the Board does not require Borrower to prepare audited financial statements, Borrower shall instead deliver to Bank, as soon as available, but no later than thirty (30) days after the last day of
Borrower’s fiscal year, a company-prepared consolidated balance sheet and income statement covering Borrower’s consolidated operations during such fiscal year certified by a Responsible Officer and in a

  
 2 

 
form acceptable to Bank; and provided, further, however, that upon the occurrence of an IPO and at all times thereafter, Audited Financial Statements shall be delivered within five (5) days
after Borrower files any 10-K with the SEC; 
 2.2    Section 6.6
(Access to Collateral; Books and Records). Section 6.6 of the Loan Agreement is hereby amended by deleting the last sentence therein of such Section in its entirety and replacing it with the following: 

In the event Borrower and Bank schedule an audit more than eight (8) days in advance, and Borrower cancels or seeks to or reschedules the
audit with less than eight (8) days written notice to Bank, then (without limiting any of Bank’s rights or remedies) Borrower shall pay Bank a fee of Two Thousand Dollars ($2,000) plus any out-of-pocket expenses incurred by Bank to compensate Bank for the anticipated costs and expenses of the cancellation nor rescheduling. 

2.3    Section 6.12 (Online Banking). Section 6.12(b) of the Loan Agreement is hereby amended by
deleting it in its entirety and replacing it with the following: 
 (b)    Comply with the terms of the
Bank’s Online Banking Agreement as in effect from time to time and ensure that all persons utilizing Bank’s online banking platform are duly authorized to do so by an Administrator. Bank shall be entitled to assume the authenticity,
accuracy and completeness on any information, instruction or request for a Credit Extension submitted via Bank’s online banking platform and to further assume that any submissions or requests made via Bank’s online banking platform have
been duly authorized by an Administrator. 
 2.4    Section 6.13 (Formation or Acquisition of
Subsidiaries). Section 6.13 of the Loan Agreement is hereby amended by deleting the first sentence leading up to clause (a) therein of such Section, and replacing it with the following: 

Notwithstanding and without limiting the negative covenants contained in Sections 7.3 and 7.7 hereof, at the time that Borrower or any
Guarantor forms any direct or indirect Subsidiary or acquires any direct or indirect Subsidiary after the Effective Date (including, without limitation, pursuant to a Division), upon Bank’s request in its sole and absolute discretion, Borrower
and such Guarantor shall 
 2.5    Section 7.1 (Dispositions). Section 7.1 of the Loan Agreement is
hereby amended by deleting the first sentence leading up to clause (a) therein of such Section, and replacing it with the following: 

Convey, sell, lease, transfer, assign, or otherwise dispose of (including, without limitation, pursuant to a Division) (collectively,
“Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers 

  
 3 

 2.6    Section 7.2 (Changes in Business, Management,
Ownership, or Business Locations). Section 7.2 of the Loan Agreement is hereby amended by adding the following sentence at the end of the last paragraph of such Section: 

If Borrower intends to add any new offices or business locations, including warehouses, containing in excess of Two Million Dollars
($2,000,000) of Borrower’s assets or property, then Borrower will first receive the written consent of Bank, and the landlord of any such new offices or business locations, including warehouses, shall execute and deliver a landlord consent in
form and substance satisfactory to Bank. 
 2.7    Section 7.3 (Mergers or Acquisitions). Section 7.3
of the Loan Agreement is hereby amended by deleting such Section in its entirety and replacing it with the following: 

7.3    Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to
merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person (an “Acquisition”) (including, without limitation, by
the formation of any Subsidiary or pursuant to a Division) other than in connection with a Permitted Acquisition, provided that a Subsidiary may merge or consolidate into another Subsidiary or into Borrower. 

2.8    Section 13.1 (Definitions). 

(a)    The following terms and their respective definitions set forth in Section 13.1 of the Loan Agreement are hereby
amended by deleting them in their entirety and replacing them with the following: 
 “Administrator” is an individual that
is named: 
 (a)    as an “Administrator” in the “SVB Online Services” form completed
by Borrower with the authority to determine who will be authorized to use SVB Online Services (as defined in Bank’s Online Banking Agreement as in effect from time to time) on behalf of Borrower; and 

(b)    as an Authorized Signer of Borrower in an approval by the Board. 

“Applicable Number” is thirty-six (36). 

“Term Loan Amortization Date” is January 1, 2020. 

“Tranche B Draw Period” is the period of time commencing on October 1, 2018 and continuing through the
earlier to occur of (a) December 31, 2019 and (b) the occurrence and continuance of an Event of Default. 

(b)    The defined term “Monthly Financial Statements” and its definition as set forth in
Section 13.1 of the Loan Agreement are hereby deleted in their entirety and all occurrences of and references to such term in the Loan Agreement are hereby deleted in their entirety and from and after the date of this Amendment shall be of no
further force and effect under the Loan Agreement. 

  
 4 

 (c)    The following new defined term and its respective definition are
hereby inserted alphabetically in Section 13.1 of the Loan Agreement: 
 “Division” means, in reference
to any Person which is an entity, the division of such Person into two (2) or more separate Persons, with the dividing Person either continuing or terminating its existence as part of such division, including, without limitation, as
contemplated under Section 18-217 of the Delaware Limited Liability Company Act for limited liability companies formed under Delaware law, or any analogous action taken pursuant to any other applicable
law with respect to any corporation, limited liability company, partnership or other entity. 
 “IPO” means,
Borrower’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Securities Exchange Act of 1933, as amended. 

“Period-Ending Financial Statements” is defined in Section 6.2(c). 

2.9    Compliance Certificate. The Compliance Certificate attached to the Loan Agreement as Exhibit B
is hereby replaced in its entirety with the Compliance Certificate attached hereto as Exhibit B. From and after the date hereof, all references in the Loan Agreement to the Compliance Certificate shall be deemed to refer to the Compliance
Certificate in the form attached hereto as Exhibit B. 
 3.    Limitation of Amendments. 

3.1    The amendments set forth in Section 2, above, are effective for the purposes set forth herein and shall
be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now
have or may have in the future under or in connection with any Loan Document. 
 3.2    This Amendment shall be
construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall
remain in full force and effect. 
 4.    Representations and Warranties. To induce Bank to enter into
this Amendment, Borrower hereby represents and warrants to Bank as follows: 
 4.1    Immediately after giving
effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to
an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing; 

4.2    Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations
under the Loan Agreement, as amended by this Amendment; 

  
 5 

 4.3    The organizational documents of Borrower delivered to Bank
as of the date hereof remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect; 

4.4    The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations
under the Loan Agreement, as amended by this Amendment, have been duly authorized; 
 4.5    The execution and
delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower,
(b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the
organizational documents of Borrower; 
 4.6    The execution and delivery by Borrower of this Amendment and the
performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any
governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made; and 

4.7    This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower,
enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating
to or affecting creditors’ rights. 
 5.    Integration. This Amendment and the Loan Documents
represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this
Amendment and the Loan Documents merge into this Amendment and the Loan Documents. 
 6.    Counterparts.
This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument. 

7.    Effectiveness. This Amendment shall be deemed effective upon (a) the due execution and
delivery to Bank of this Amendment by each party hereto, (b) Borrower’s payment of a fully-earned, non-refundable amendment fee in an amount equal to Fifty Thousand Dollars ($50,000), and
(c) Borrower’s payment of Bank’s legal fees and expenses incurred in connection with this Amendment. 
 [Signature page
follows.] 

  
 6 

 IN WITNESS WHEREOF, the parties hereto
have caused this Amendment to be duly executed and delivered as of the date first written above. 
  

			
	BORROWER:
	
	10X GENOMICS, INC.
		
	By:	 	/s/ Serge Saxonov
	Name:	 	Serge Saxonov
	Title:	 	Chief Executive Officer

  

			
	BANK:
	
	SILICON VALLEY BANK
		
	By:	 	/s/ Peter Sletteland
	Name:	 	Peter Sletteland
	Title:	 	Vice President

 [Signature Page to First Amendment to Second Amended and Restated Loan and Security Agreement] 

 EXHIBIT B 

COMPLIANCE CERTIFICATE 
  

					
	TO:	 	SILICON VALLEY BANK	  	Date:                            
	FROM:	 	10X GENOMICS, INC.	  	

 The undersigned authorized officer of 10X GENOMICS, INC., a Delaware corporation
(“Borrower”), certifies that under the terms and conditions of the Second Amended and Restated Loan and Security Agreement between Borrower and Bank (the “Agreement”), (1) Borrower is in complete compliance for
the period ending _______________ with all required covenants except as noted below, (2) there are no Events of Default, (3) all representations and warranties in the Agreement are true and correct in all material respects on this date
except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided,
further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, (4) Borrower, and each of its Subsidiaries, has timely filed all
required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except as otherwise permitted pursuant to the terms of Section 5.9 of the
Agreement, and (5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries, if any, relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Bank.
Attached are the required documents supporting the certification. The undersigned certifies that the attached financial statements are prepared in accordance with GAAP consistently applied from one period to the next except as explained in an
accompanying letter or footnotes, and with respect to unaudited financial statements, subject to normal year-end adjustments and for the absence of footnotes. The undersigned acknowledges that no borrowings
may be requested at any time or date of determination that Borrower is not in compliance with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered. Capitalized terms used but not
otherwise defined herein shall have the meanings given them in the Agreement. 
  

					
	 Please indicate compliance status by circling Yes/No under “Complies” column.

 

	 Reporting Covenants
	  	 Required
	  	 Complies

	Period-Ending Financial Statements with 
Compliance Certificate (“CC”)	  	Either (i) monthly within 30 days if no IPO has occurred, or (ii) upon an IPO, quarterly within (A) 45 days for each fiscal quarter of the first 3 quarters of Borrower’s fiscal year and (B) the
earlier of (x) 90 days after the last day of Borrower’s fiscal year or (y) 5 days after filing any 10-K with SEC.	  	Yes     No
		  		  	
	Annual financial statements	  	(a) if audited is required by the Board, FYE within 270 days (CPA Audited) and (b) if audited is not required by the Board, FYE within 30 days (company-prepared). Upon an IPO, within 5 days after filing with SEC.	  	Yes     No
		  		  	
	10-Q, 10-K and 8-K	  	 Within 5 days after filing with SEC.
	  	Yes     No
		  		  	
	A/R & A/P Agings; General Ledger	  	Monthly within 30 days*	  	Yes     No
		  		  	
	Borrowing Base Reports	  	Upon each (i) Advance request, (ii) monthly within 30 days,* and (iii) at Bank’s option in its sole discretion while there are outstanding Advances, weekly within 5 days.	  	Yes     No
		  		  	
	Board-approved projections	  	FYE within 60 days and within 30 days of any updates or amendments thereto.	  	Yes     No
		  		  	

  
 B-1 

							
	 *   Provided, however, this reporting shall not be required for any
period if there were no Advances outstanding during such period through and including the date that the reporting would otherwise be required to be delivered
  

	 Financial Covenant
	  	 Required
	  	 Actual
	  	 Complies

	Maintain on a Monthly Basis: Minimum Revenue
_________________ (trailing 6 month)	  	Tested as of the last day of each month,
minimum GAAP revenue for the trailing 6
month period then ended, of at least 70% of
Borrower’s projected performance for such
month as
outlined in Borrower’s 2018- 2019
Financial Projections	  	$                                   
 	  	Yes     No

 Other Matters 
  

					
	Have there been any (i) amendments of or other changes to the capitalization table of Borrower or (ii) amendments or other changes to the Operating Documents of Borrower or any of its Subsidiaries? If yes, provide
copies of any such amendments or changes with this Compliance Certificate.	  	Yes	  	No

 The following are the exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions
to note.”) 
  
  

 
  
  

									
	10X GENOMICS, INC.	 		 	BANK USE ONLY
					
	By:	 	 	 		 	Received by:	 	 
	  
 Name:
	 	 	 		 		 	 AUTHORIZED SIGNER

					
	Title:	 	 	 		 	Date:	 	 
					
		 		 		 	Verified:	 	 
		 		 		 		 	 AUTHORIZED SIGNER

					
		 		 		 	Date:	 	 
				
		 		 		 	Compliance Status:     Yes    No

  
 B-2EX-10.5

 Exhibit 10.5 

Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly
disclosed. 
 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is entered into as of this 26th day of September, 2013 (the “Effective Date”),
by and between 10X Technologies, Inc., a Delaware Corporation having a place of business at 7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566 (“Licensee”) and President and Fellows of Harvard College, an educational and
charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Holyoke Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”). 

WHEREAS, the technologies claimed in the Patent Rights (as defined below) were developed in research conducted by Harvard researchers
David Weitz, Ph.D., together with others, and by Frederick Roth, Ph.D., together with others; 
 WHEREAS, Licensee wishes to obtain a
license under the Patent Rights; 
 WHEREAS, Harvard desires to have products and services based on the inventions described in the
Patent Rights developed and commercialized to benefit the public; and 
 WHEREAS, Licensee has represented to Harvard, in order to
induce Harvard to enter into this Agreement, that Licensee shall commit itself to commercially reasonable efforts to develop and commercialize such products and services, and to obtain regulatory approval for such products and services if necessary;

 NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows: 

 

	1.	 Definitions. 

Whenever used in this Agreement with an initial capital letter, the terms defined in this Article 1, whether used in the singular or the
plural, will have the meanings specified below. 
 1.1. “[***] Co-Exclusive Field”
means analysis and use of single or multiple cells in drops. 
 1.2. “[***] Patent Rights” means, to the extent owned
and controlled by Harvard: (a) the patents and patent applications listed in Exhibit 1.2 with respect to [***], (including any PCT and/or U.S. utility application claiming priority to such application(s) that are filed on or before the one year
conversion date of such application(s)); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent application identified in (a); (c) any
patents issuing on any patent application identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a
continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date
of, and is directed specifically to subject matter specifically described 

 
in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or
(c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like of any patents and patent applications
identified in (a) through (e). 
 1.3. “[***] Patent Rights” means, to the extent owned and controlled by Harvard:
(a) the patents and patent applications listed in Exhibit 1.3 with respect to [***], (including any PCT and/or U.S. utility application claiming priority to such application(s) that are filed on or before the one year conversion date of such
application(s)); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent application identified in (a); (c) any patents issuing on any
patent application identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a
continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date
of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application
identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like of any patents and
patent applications identified in (a) through (e). 
 1.4. “Affiliate” means, with respect to a person, organization
or entity, any person, organization or entity controlling, controlled by or under common control with, such person, organization or entity. For purposes of this definition only, “control” of another person, organization or entity will mean
the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether through the ownership of voting securities, by contract or otherwise.
Without limiting the foregoing, control will be presumed to exist when a person, organization or entity (a) owns or directly controls fifty percent (50%) or more of the outstanding voting stock or other ownership interest of the other
organization or entity or (b) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the other organization or entity. The parties acknowledge that in the case of
certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such cases such lower percentage
will be substituted in the preceding sentence. 
 1.5. “Calendar Quarter” means each of the periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31 during the Term. 

1.6. “Development Milestones” means the development and commercialization milestones set forth in Exhibit 1.6 hereto. 

1.7. “Development Plan” means the plan for the development and commercialization of Licensed Products and Licensed Services
attached hereto as Exhibit 1.7, as such plan may be adjusted from time to time pursuant to Section 3.2. 

  
 2 

 1.8. “Exclusive Patent Rights” means, in each case to the extent owned and
controlled by Harvard: (a) the patents and patent applications listed in Exhibit 1.8 with respect to [***] (including any PCT and/or U.S. utility application claiming priority to such application(s) that are filed on or before the one year
conversion date of such application(s)); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent application identified in (a); (c) any
patents issuing on any patent application identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a
continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date
of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application
identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like of any patents and
patent applications identified in (a) through (e). 
 1.9. “Field” means [***]. 

1.10. “Licensed Method” means any method or process, the practice of which falls within the scope of a Valid Claim pending in
the country where the method or process is performed. 
 1.11. “Licensed Product” means on a
country-by-country basis, any product, the making, using, selling, offering for sale, importing or exporting in the country in question would (without the license
granted hereunder) infringe directly, indirectly by inducement of infringement, or indirectly by contributory infringement, at least one Valid Claim (were it to have issued) pending in that country or Valid Claim issued in that country. 

1.12. “Licensed Service” means any service performed for or on behalf of a third party on a fee-for-service basis, the performance of which falls within the scope of a Valid Claim pending in the country where the service is performed. 

1.13. “Net Revenues” means the gross amount billed or invoiced by Licensee, its Affiliates and Sublicensees (in each case the
“Invoicing Entity”), on all sales of Licensed Products and Licensed Services less: (a) credits for claims, allowances, or returned goods; (b) any charges for insurance, freight, and other transportation costs directly related to
the delivery of Licensed Products; (c) any tax, tariff, or governmental charge levied on the sales of a Licensed Product or performance of a Licensed Service (but excluding what are commonly known as value-added taxes, franchise taxes, gross
receipts taxes, income taxes or similar government charges) borne by the seller thereof; and (d) any import or export duties or their equivalent borne by the seller and imposed on the import or export of Licensed Products for sale. Sales of
Licensed Products by Licensee to any Affiliate which is a reseller thereof shall be excluded, and only the subsequent sale of such Licensed Products by Affiliates of Licensee to unrelated parties shall be deemed Net Revenues hereunder. For the
avoidance of doubt, Net Revenues shall not include (i) transfers of Licensed Product or performance of a Licensed Service for the testing or control of Licensed 

  
 3 

 
Products or Licensed Services; (ii) promotional distribution or demonstration of Licensed Products or Licensed Services to potential purchasers where no monetary or other consideration is
received by Licensee (other than reimbursement for transportation or other ordinary business expenses actually incurred), its Affiliate or Sublicensee; (iii) distribution of Licensed Products or performance of Licensed Services solely for
research on behalf of Licensee where no monetary or other consideration is received by Licensee; (iv) any transfer of Licensed Product or performance of Licensed Service made solely in connection with a regulatory approval process;
(v) transfer of Licensed Product to an Affiliate solely for later resale to or use by an end consumer (however, such sale to the end consumer by the Affiliate shall be included in Net Revenues); or (vi) any other deductions not listed
above to the extent that such deduction is, after the Effective Date, a new bona fide deduction from gross invoiced sales under such new rules of U.S. Generally Accepted Accounting Principles (GAAP). 

In the event that a Licensed Product is sold or a Licensed Service is performed by an Invoicing Entity in combination with another component
that is also sold by such Invoicing Entity (and such other component if sold alone would not be subject to a royalty payment under this Agreement), then Net Revenue on the combination product shall be calculated by multiplying Net Revenues of the
combination product by the fraction A/A+B, where A is the gross selling price of the Licensed Product sold, or Licensed Service performed separately, and B is the gross selling price, of the other component sold separately. For clarity, this
formulation shall not be applied in the case of components not sold separately by the Invoicing Entity; in such case, the full royalty rate in Section 4.3.1 shall apply. 

1.14. “Non-Exclusive Patent Rights” means, in each case to the extent owned and
controlled by Harvard: (a) the patents and patent applications listed in Exhibit 1.14 with respect to [***], (including any PCT and/or U.S. utility application claiming priority to such application(s) that are filed on or before the one
year conversion date of such application(s)); (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent application identified in (a); (c)
any patents issuing on any patent application identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date of, and is directed specifically to
subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or (c) or of the
claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like of any patents and patent applications identified in
(a) through (e). 
 1.15. “Non-Royalty Sublicense Income” means any payments
or other consideration that Licensee or any of its Affiliates receives in consideration for a Sublicense, other than royalties based on Net Revenues. If Licensee or its Affiliate receives non-cash
consideration in connection with a Sublicense or in the case of transactions not at arm’s length, Non-Royalty Sublicense Income will be calculated based on the fair market value of such consideration or
transaction, at the time of the transaction, assuming an arm’s-length transaction made in the ordinary course of business. Non-Royalty Sublicense Income does not
include: (a) equity purchased at fair market value; or (b) bona fide research and development funding related to potential Licensed Products or Licensed Services. 

  
 4 

 1.16. “Patent Rights” means the [***] Patent Rights, the [***] Patent
Rights, the Exclusive Patent Rights and the Non-Exclusive Patent Rights. 
 1.17.
“Sublicense” means: (a) any right granted, license given or agreement entered into by Licensee to or with any other person or entity, under or with respect to or permitting any use or exploitation of any of the Patent Rights or
otherwise permitting the development, manufacture, marketing, distribution, use and/or sale of Licensed Products, practice of Licensed Methods or performance of Licensed Services; (b) any option or other right granted by Licensee to any other
person or entity to negotiate for or receive any of the rights described under clause (a); or (c) any standstill or similar obligation undertaken by Licensee toward any other person or entity not to grant any of the rights described in clause
(a) or (b) to any third party; in each case regardless of whether such grant of rights, license given or agreement entered into is referred to or is described as a sublicense. 

1.18. “Sublicensee” means any person or entity granted a Sublicense. 

1.19. “Term” means the term of this Agreement as set forth in Section 10.1. 

1.20. “Territory” means the United States of America. 

1.21. “Third Party Proposed Product or Service” means an actual or potential Licensed Product or Licensed Service that is for
an application or market segment for which Harvard reasonably believes a Licensed Product or Licensed Service is not being actively developed, performed and/or commercialized by Licensee, its Affiliates or any Sublicensee hereunder 

1.22. “Valid Claim” means: (a) a claim of an issued and unexpired patent within the Patent Rights that has not
(i) been held revoked, unenforceable, unpatentable or invalid by a decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (ii) been rendered unenforceable through
disclaimer or otherwise, (iii) been abandoned, (iv) lapsed or expired, or (v) been lost through an interference or opposition proceeding without any right of appeal or review; or (b) a pending claim of a pending patent
application within the Patent Rights that (i) has been asserted and continues to be prosecuted in good faith and (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling. 

 

	2.	 License. 

2.1. License Grant. Subject to the terms and conditions set forth in this Agreement, Harvard hereby grants to Licensee: 

(i) an exclusive (except as set forth below), worldwide, royalty-bearing license under its interest in: 

(a) the Exclusive Patent Rights to make, have made, to offer for sale, to sell and to have sold Licensed Products in the Field
and to perform Licensed Services in the Field; 

  
 5 

 (b) the [***] Patent Rights to make, have made, to offer for sale, to sell
and to have sold Licensed Products in the Field except in the [***] Co-Exclusive Field and to perform Licensed Services in the Field except in the [***] Co-Exclusive
Field; and 
 (c) the [***] Patent Rights to make, have made, to offer for sale, to sell, and to have sold Licensed Products
in all fields and to perform Licensed Services in all fields; 
 (ii) a
non-exclusive, worldwide, royalty-bearing license under its interest in the Non-Exclusive Patent Rights (A) to make, have made, to offer for sale, to sell, and to
have sold Licensed Products in the Field and, with respect to the Non-Exclusive Patent Rights related to Harvard Case Number [***], in the Territory, and (B) to perform Licensed Services in the Field,
and, with respect to the Non-Exclusive Patent Rights related to Harvard Case Number [***], in the Territory; and 

(c) a co-exclusive, worldwide, royalty-bearing license under its interest in the [***]
Patent Rights to make, have made, to offer for sale, to sell, and to have sold Licensed Products in the [***] Co-Exclusive Field, and to perform Licensed Services in the [***]
Co-Exclusive Field; provided, however: 
 2.1.2. Harvard retains the right, for itself and
for other not-for-profit research organizations, to practice the Patent Rights within the scope of the license granted above, solely for
non-commercial research, educational and scholarly purposes; and 
 2.1.3. the United States
federal government retains rights in the Patent Rights pursuant to 35 U.S.C. §§ 200-212 and 37 C.F.R. § 401 et seq., and any right granted in this Agreement greater than that permitted under 35
U.S.C. §§ 200-212 or 37 C.F.R. § 401 et seq. will be subject to modification as may be required to conform to the provisions of those statutes and regulations; and 

2.1.4. [***] 

  
 6 

 2.2. Affiliates. The license granted to Licensee under Section 2.1 includes the
right to have some or all of Licensee’s rights or obligations under this Agreement exercised or performed by one or more of Licensee’s Affiliates on Licensee’s behalf; provided, however, that: 

2.2.1. no such Affiliate shall be entitled to grant, directly or indirectly, to any third party any right of whatever nature under, or
with respect to, or permitting any use or exploitation of, any of the Patent Rights, including any right to develop, manufacture, market or sell Licensed Products or to practice Licensed Methods or perform Licensed Services; and 

2.2.2. any act or omission taken or made by an Affiliate of Licensee under this Agreement will be deemed an act or omission by Licensee
under this Agreement. 
 2.3. Sublicenses. 

2.3.1. Sublicense Grant. Licensee will be entitled to grant Sublicenses to third parties under the license granted pursuant to
Section 2.1 subject to the terms of this Section 2.3. Any such Sublicense shall be on terms and conditions in compliance with and not inconsistent with the terms of this Agreement. 

2.3.2. Sublicense Agreements. Licensee shall grant sublicenses pursuant to written agreements, which will be subject and subordinate to
the terms and conditions of this Agreement. Such Sublicense agreements will contain, among other things, the following: 
 2.3.2.1.
all provisions necessary to ensure Licensee’s ability to perform its obligations under this Agreement; 
 2.3.2.2. a
section substantially the same as Article 9 of this Agreement, which also will state that the Indemnitees (as defined in Section 9.1) are intended third party beneficiaries of such Sublicense agreement for the purpose of enforcing such
indemnification; 
 2.3.2.3. a provision clarifying that, in the event of termination of the license set forth in Section 2.1
(in whole or in part (e.g., termination in a particular country)), any existing Sublicense agreement shall terminate to the extent of such terminated license; 

2.3.2.4. a provision prohibiting the Sublicensee from sublicensing its rights under such Sublicense agreement; and 

2.3.2.5. a provision prohibiting the Sublicensee from assigning the Sublicense agreement without the prior written consent of Harvard,
except that Sublicensee may assign the Sublicense agreement without prior consent of Harvard to: (i) an Affilliate of such Sublicensee; or (ii) a successor in connection with the merger, consolidation or sale of all or substantially all of
its assets or that portion of its business to which the Sublicense agreement relates; provided, that any such assignee agrees in writing to be bound by the terms of such Sublicense agreement. 

  
 7 

 2.3.3. Delivery of Sublicense Agreement. Licensee shall furnish Harvard with a fully
executed copy of any Sublicense agreement redacted for information not applicable to this Agreement, promptly after its execution. Harvard shall keep all such copies in its confidential files and shall use them solely for the purpose of monitoring
Licensee’s and Sublicensees’ compliance with their obligations hereunder and enforcing Harvard’s rights under this Agreement. 

2.3.4. Breach by Sublicensee. Any act or omission by a Sublicensee that would have constituted a breach of this Agreement had it been
an act or omission by Licensee shall constitute a breach of this Agreement, provided that Licensee fails to cure such breach within ninety (90) days after it first receives notice of such breach. 

2.4. Third Party Proposed Products and Services. 

2.4.1. If during the period beginning on or after the third anniversary of the Effective Date, a third party makes a bona fide proposal
to Harvard for developing a Third Party Proposed Product or Service, Harvard may, at its discretion, notify Licensee of the third party’s proposal and provide Licensee with all relevant information about such bona fide proposal in order to
comply with the obligations under this Section 2.4, including the identity of such third party and the terms proposed by such third party. 

2.4.2. Within sixty (60) days after the receipt of such notification from Harvard, Licensee shall notify Harvard whether
(a) it is interested in pursuing such Third Party Proposed Product or Service itself or through an Affiliate, (b) it is interested in discussing a potential Sublicense with such third party with respect to such Third Party Proposed Product
or Service, (c) rights to develop such Third Party Proposed Product or Service have already been granted to a Sublicensee, or (d) it has no interest in pursuing such Third Party Proposed Product or Service, resulting in the consequences
described below. 
 2.4.2.1. If Licensee notifies Harvard that it is interested in developing such Third Party Proposed Product or
Service itself or through an Affiliate or existing Sublicensee, then the parties shall update Exhibit 1.7 with reasonable relevant due diligence milestones. Harvard acknowledges that it may be considered reasonable for any such updated development
plan or milestones to give Licensee flexibility for and to take into account Licensee’s long-term business strategy for development of Licensed Products and Licensed Services generally. Toward that end, it may be considered reasonable for any
development plan and development milestones to include a schedule under which activities with respect to the Third Party Proposed Product or Service are initiated only after completion of activities with respect to other Licensed Products or
Licensed Services. In such event, Licensee’s development plan will include a justification for delaying the initiation of such activities. 

2.4.2.2. If Licensee notifies Harvard that it is interested in discussing a potential Sublicense with such third party with respect to
such Third Party Proposed Product or Service, Harvard will introduce such third party to Licensee, and Licensee will negotiate in good faith and execute a Sublicense agreement with such third party having commercially reasonable terms. Harvard
acknowledges and agrees that it may not be possible for Licensee to negotiate successfully a Sublicense agreement having commercially reasonable terms, and in such case, Licensee shall notify Harvard in accordance with the procedures set forth in
Section 2.4.2.4. below. 

  
 8 

 2.4.2.3. If Licensee notifies Harvard that rights to develop such Third Party
Proposed Product or Service have already been granted to a Sublicensee, then Licensee shall undertake to inform such Sublicensee of the third party’s proposal. Such Sublicensee shall have no obligation to develop such Third Party Proposed
Product or Service, and in such case, Licensee shall notify Harvard in accordance with the procedures set forth in Section 2.4.2.4 below. 

2.4.2.4. If Licensee notifies Harvard that it does not wish to pursue such Third Party Proposed Product or Service, then the parties
will negotiate in good faith to determine a mutually-acceptable resolution for developing or not developing such Third Party Proposed Product or Service. If Licensee requests that the Third Party Proposed Product or Service not be developed,
Licensee must provide a reasonable explanation as to how the Third Party Proposed Product or Service would compete with Licensee’s present or future business. 

2.5. No Other Grant of Rights. Except as expressly provided herein, nothing in this Agreement will be construed to confer any ownership
interest, license or other rights upon Licensee by implication, estoppel or otherwise as to any technology, intellectual property rights, products or biological materials of Harvard, or any other entity, regardless of whether such technology,
intellectual property rights, products or biological materials are dominant, subordinate or otherwise related to any Patent Rights. 
  

	3.	 Development and Commercialization. 

3.1. Diligence. Licensee shall use commercially reasonable efforts and shall cause its Affiliates and Sublicensees to use commercially
reasonable efforts: (a) to develop or have developed Licensed Products and Licensed Services in accordance with the Development Plan; (b) to introduce or have introduced Licensed Products and Licensed Services into the commercial market;
and (c) to market or have marketed Licensed Products and Licensed Services following such introduction into the market. In addition, Licensee, by itself or through its Affiliates or Sublicensees, shall achieve each of the Development Milestones
within the time periods specified in Exhibit 1.6. 
 3.2. Adjustments of Development Plan. Licensee will be entitled, from time to
time, to make such adjustments to the then applicable Development Plan as Licensee believes, in its good faith judgment, are needed in order to improve Licensee’s ability to meet the Development Milestones. 

3.3. Reporting. Within ninety (90) days after the end of each calendar year, Licensee shall furnish Harvard with a written report
summarizing its, its Affiliates’ and its Sublicensees’ efforts during the prior year to develop and commercialize Licensed Products and Licensed Services, including: (a) research and development activities; (b) commercialization
efforts; and (c) marketing efforts. Each report must contain a sufficient level of detail for Harvard to assess whether Licensee is in compliance with its obligations under Section 3.1 and a discussion of intended efforts for the then
current year. Together with each report, Licensee shall provide Harvard with a copy of the then current Development Plan. 

  
 9 

 3.4. Failure to Meet Development Milestone; Opportunity to Cure. If Licensee believes
that it will not meet its obligations pursuant to Section 3.1, it may notify Harvard in writing. Licensee shall include with such notice (a) a reasonable explanation of the reasons for such failure (“Explanation”) and (b) a
reasonable, detailed, written plan for promptly achieving a reasonable extended and/or amended milestone or plan (“Plan”). If Licensee so notifies Harvard, but fails to provide Harvard with both an Explanation and Plan, then Licensee will
have an additional seventy-five (75) days to meet such milestone or plan. Licensee’s failure to do so shall constitute a material breach of this Agreement and Harvard shall have the right to terminate this Agreement forthwith. If Licensee
so notifies Harvard and provides Harvard with an Explanation and Plan, both of which are acceptable to Harvard in its reasonable discretion, then Exhibit 1.6 will be amended automatically to incorporate the Plan. If Licensee so notifies Harvard and
provides Harvard with an Explanation and Plan, but the Explanation is not acceptable to Harvard in its reasonable discretion (e.g., Licensee asserts development preference for a non-Licensed Product or non-Licensed Service), then Licensee will have an additional seventy-five (75) days or until the original deadline of the relevant Development Milestone, whichever is later, to meet such milestone.
Licensee’s failure to do so shall constitute a material breach of this Agreement and Harvard shall have the right to terminate this Agreement forthwith. If Licensee so notifies Harvard and provides Harvard with an Explanation and Plan, but the
Plan is not acceptable to Harvard in its reasonable discretion, then Harvard will explain to Licensee why the Plan is not acceptable and provide Licensee with suggestions for an acceptable Plan. Licensee will have one opportunity to provide Harvard
with an acceptable Plan within ninety (90) days, during which time Harvard agrees to work with Licensee in its effort to develop an acceptable Plan. If, within such ninety (90) days, Licensee provides Harvard with an acceptable Plan, then
Exhibit 1.6 will be amended automatically to incorporate the extended and/or amended Plan. If, within such ninety (90) days, Licensee fails to provide an acceptable Plan, then Licensee will have an additional thirty (30) days or until the
original deadline of the relevant Development Milestone, whichever is later, to meet such milestone. Licensee’s failure to do so shall constitute a material breach of this Agreement and Harvard shall have the right to terminate this Agreement
forthwith. For clarity, if Licensee fails to achieve a Development Milestone and does not avail itself of the procedure set forth in this Section 3.4, such failure shall be a material breach that entitles Harvard to proceed under
Section 10.2.2.1. 
  

	4.	 Consideration for Grant of License. 

4.1. License Issuance Fee. Licensee agrees to pay Harvard a non-refundable license fee of [***].

 4.2. Annual License Maintenance Fees. Licensee agrees to pay Harvard annual license maintenance fee as follows: 

[***] 
 Each annual license maintenance fee
shall be due and payable on the first business day in January of the applicable year, and creditable against any royalty amounts payable under Section 4.3.1 below with respect to Licensed Products sold and Licensed Services performed in the
same anniversary year that such annual license maintenance fee was due. 

  
 10 

 4.3. Royalty on Net Revenues. 

4.3.1. Rate. An amount equal to [***] of all Net Revenues of Licensed Products and Licensed Services, provided, however, that no
royalty will be due for any Net Revenues of Licensed Products or Licensed Services, the making, selling, use or performance of which falls solely within the scope of a Valid Claim that has been pending without issuance for more than three
(3) years following the date of issuance of the first substantive patent office action considering the patentability of such claim by the relevant patent office in the country or territory in which such claim is pending (after which time such
pending claim shall cease to be a Valid Claim for purposes of Section 4.3.1 of this Agreement unless and until such claim becomes an issued claim) (each, a “Stale Claim”). For clarity, on a country-by-country basis, as long as a Licensed Product or Licensed Service is covered by at least one Valid Claim that is not a Stale Claim, the full royalty rate is due and payable to Harvard. 

4.3.2. Patent Challenge. If Licensee or its Affiliate (“Challenging Party”) commences an action in which it challenges the
validity, enforceability or scope of any of the Patent Rights (a “Challenge Proceeding”), the royalty rate specified in Section 4.3.1 for the party who commences the Challenging Proceeding will be doubled with respect to Net Revenues
of Licensed Products or Licensed Services that are sold or performed during the pendency of such Challenge Proceeding. If the outcome of such Challenge Proceeding is a determination against the Challenging Party, (a) the royalty rate
specified in Section 4.3.1 with respect to Net Revenues of Licensed Products or Licensed Services that are covered by the Patent Rights that are the subject of such Challenge Proceeding shall remain at such doubled rate for the party who
commences the Challenging Proceeding and (b) the party who commences the Challenging Proceeding shall reimburse Harvard for all reasonable out-of-pocket expenses
incurred by Harvard (including reasonable attorneys’ fees) in connection with such Challenge Proceeding. 
 4.3.3. Third Party
Royalty Set-Off. If Licensee is obligated to obtain a patent license from a third party in order to exercise its rights hereunder with respect to the making and selling of Licensed Products and/or the
performance or sale of Licensed Services, it may offset [***] of any royalty payments due thereunder with respect to sales of Licensed Products or Licensed Services against the royalty payments that are due to Harvard with respect to Net Revenues of
such Licensed Products or Licensed Services in such country; provided that in no event shall (a) the royalty payments to Harvard with respect to such Licensed Products or Licensed Services be reduced by more than [***] of the amount otherwise
due and (b) the percentage offset that Licensee is entitled to make against royalty payments due to Harvard be greater than any percentage offset that Licensee is entitled to make against royalty payments due to such third party licensor on
account of royalty payments made to Harvard with respect to such Licensed Product or Licensed Service. 
 4.4. Non-Royalty Sublicense Income. Licensee will pay Harvard an amount equal to [***] of all Non-Royalty Sublicense Income. 

  
 11 

	5.	 Reports; Payments; Records. 

5.1. Reports and Payments. 

5.1.1. Reports. Within sixty (60) days after the conclusion of each Calendar Quarter commencing with the first Calendar Quarter in
which Net Revenues are generated or Non-Royalty Sublicense Income is received, Licensee shall deliver to Harvard a report containing the following information (in each instance, with a Licensed Product-by-Licensed Product and Licensed Service-by-Licensed Service and country-by-country breakdown): 
 5.1.1.1. the number of
units of Licensed Products sold, leased or otherwise transferred and Licensed Services performed by Invoicing Entities for the applicable Calendar Quarter; 

5.1.1.2. the gross amount billed or invoiced for Licensed Products sold, leased or otherwise transferred and Licensed Services
performed by Invoicing Entities during the applicable Calendar Quarter; 
 5.1.1.3. a calculation of Net Reventies for the
applicable Calendar Quarter, including an itemized listing of allowable deductions; 
 5.1.1.4. a detailed accounting of all Non-Royalty Sublicense Income received during the applicable Calendar Quarter; 
 5.1.1.5. the
total amount payable to Harvard in U.S. Dollars on Net Revenues and Non-Royalty Sublicense Income for the applicable Calendar Quarter, together with the exchange rates used for conversion; and 

5.1.1.6. a list of Harvard Case numbers for all Patent Rights that have Valid Claims covering the Licensed Products and Licensed
Services. 
 Each such report shall be certified on behalf of Licensee as true, correct and complete in all material respects. If no amounts
are due to Harvard for a particular Calendar Quarter, the report shall so state. 
 5.1.2. Payment. Within sixty (60) days after
the end of each Calendar Quarter, Licensee shall pay Harvard all amounts due with respect to Net Revenues and Non-Royalty Sublicense Income for the applicable Calendar Quarter. 

5.2. Payment Currency. All payments due under this Agreement will be paid in U.S. Dollars. Conversion of foreign currency to U.S.
Dollars will be made at the conversion rate existing in the United States (as reported in the Wall Street Journal U.S. Internet edition at www.wsj.com) on the last working day of the applicable Calendar Quarter. Such payments will be without
deduction of exchange, collection or other charges. 

  
 12 

 5.3. Records. Licensee shall maintain, and shall cause its Affiliates and
Sublicensees to maintain, complete and accurate records of Licensed Products that are made, used, sold, leased or transferred and Licensed Services performed under this Agreement, any amounts payable to Harvard in relation to such Licensed Products
and Licensed Services, and all Non-Royalty Sublicense Income received by Licensee and its Affiliates, which records shall contain sufficient information to permit Harvard to confirm the accuracy of any reports
or notifications delivered to Harvard under Section 5.1. Licensee, its Affiliates and/or its Sublicensees, as applicable, shall retain such records relating to a given Calendar Quarter for at least two (2) years after the conclusion of
that Calendar Quarter, during which time Harvard will have the right, at its expense, to cause an independent, certified public accountant (or, in the event of a non-financial audit, other appropriate auditor)
to inspect such records during normal business hours for the purposes of verifying the accuracy of any reports and payments delivered under this Agreement and Licensee’s compliance with the terms hereof. Such accountant or other auditor, as
applicable, shall not disclose to Harvard any information other than information relating to the accuracy of reports and payments delivered under this Agreement. The parties shall reconcile any underpayment or overpayment within sixty (60) days
after the accountant delivers the results of the audit. If any audit performed under this Section 5.3 reveals an underpayment in excess of five percent (5%) in any calendar year, Licensee shall reimburse Harvard for all amounts incurred in
connection with such audit. Harvard may exercise its rights under this Section 5.3 only once every year per audited entity and only with reasonable prior notice to the audited entity. 

5.4. Late Payments. Any payments by Licensee that are not paid on or before the date such payments are due under this Agreement will
bear interest at the then applicable BBA LIBOR rate. Interest will accrue beginning on the first day following the due date for payment and will be compounded quarterly. Payment of such interest by Licensee shall not limit, in any way,
Harvard’s right to exercise any other remedies Harvard may have as a consequence of the lateness of any payment. 
 5.5. Payment
Method. Each payment due to Harvard under this Agreement shall be paid by check or wire transfer of funds to Harvard’s account in accordance with written instructions provided by Harvard. If made by wire transfer, such payments shall be
marked so as to refer to this Agreement. 
 5.6. Withholding and Similar Taxes. All amounts to be paid to Harvard pursuant to this
Agreement shall be without deduction of exchange, collection, or other charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as permitted in the definition of Net Revenues.

  

	6.	 Patent Filing, Prosecution and Maintenance. 

6.1. Control. Harvard will be responsible for the preparation, filing, prosecution, protection and maintenance of all Patent Rights,
using independent patent counsel reasonably acceptable to Licensee. Harvard will: (a) instruct such patent counsel to furnish Licensee with copies of all correspondence relating to the Patent Rights from the United States Patent and Trademark
Office (USPTO) and any other patent office, as well as copies of all proposed responses to such correspondence in time for Licensee to review and comment on such response at the same time that it provides such correspondence to Harvard;
(b) give Licensee an opportunity to review the text of each patent application before filing; (c) consult with Licensee with respect thereto; (d) supply Licensee with a copy of the application as filed, together with notice of its
filing date and serial number; and (e) keep Licensee advised of the status of actual and prospective patent filings. 

  
 13 

 
Harvard shall give Licensee the opportunity to provide comments on and make requests of Harvard concerning the preparation, filing, prosecution, protection and maintenance of the Patent Rights,
and shall consider such comments and requests in good faith; however, final decision-making authority shall vest in Harvard. As long as Licensee is making timely reimbursements to Harvard in accordance with this Article 6 and not in breach of any
other material term of this Agreement, Harvard shall not abandon or allow to lapse any patent or application within the [***] Patent Rights, the [***] Patent Rights, or the Exclusive Patent Rights, unless it is legally required to do so. 

6.2. Expenses. Subject to Section 6.3 below, Licensee shall reimburse Harvard for all documented,
out-of-pocket expenses incurred by Harvard pursuant to this Article 6 within forty-five (45) days after the date of each invoice from Harvard for such expenses. If
Harvard licenses the Patent Rights to a third party and receives reimbursement from such third party, it shall reimburse Licensee for an appropriate share of such expenses. In addition, Licensee shall reimburse Harvard for an appropriate share (on a
case-by-case basis, depending on the number of licensees of the Non-Exclusive Patent Rights and the number of licensees of the
Exclusive Patent Rights outside of the Field) of all documented, out-of-pocket expenses incurred by Harvard prior to the Effective Date with respect to the preparation,
filing, prosecution, protection and maintenance of the Patent Rights, according to the following schedule: 
 [***]. 

6.3. Abandonment. If Licensee decides that it does not wish to pay for the preparation, filing, prosecution, protection or maintenance
of any Patent Rights in a particular country (“Abandoned Patent Rights”), Licensee shall provide Harvard with prompt written notice of such election. Upon receipt of such notice by Harvard, Licensee shall be released from its obligation to
reimburse Harvard for the expenses incurred thereafter as to such Abandoned Patent Rights; provided, however, that expenses authorized prior to the receipt by Harvard of such notice shall be deemed incurred prior to the notice. In the event of
Licensee’s abandonment of any Patent Rights, any license granted by Harvard to Licensee hereunder with respect to such Abandoned Patent Rights will terminate, and Licensee will have no rights whatsoever to exploit such Abandoned Patent Rights.
Harvard will then be free, without further notice or obligation to Licensee, to grant rights in and to such Abandoned Patent Rights to third parties. 

6.4. Small Entity Designation. If Licensee, its Affiliates, any Sublicensee and/or any holder of an option to obtain a Sublicense does
not qualify, or at any point during the Term ceases to qualify, as an entity entitled to pay lesser fees as provided by the USPTO (i.e., a “small entity”) or the patent office of any other country, Licensee shall so notify Harvard
immediately, in order to enable Harvard to comply with regulations regarding payment of fees with respect to Patent Rights. 
 6.5.
Marking. If required by law, Licensee shall, and shall cause its Affiliates and Sublicensees to, mark all Licensed Products sold or otherwise disposed of in such a manner as to conform with the patent laws and practice of the country to which
such products are shipped or in which such products are sold for purposes of ensuring maximum enforceability of Patent Rights in such country. 

  
 14 

	7.	 Enforcement of Patent Rights. 

7.1. Notice. In the event either party becomes aware of any possible or actual infringement of any Patent Rights with respect to
Licensed Products or Licensed Services (an “Infringement”), that party shall promptly notify the other party and provide it with details regarding such Infringement. 

7.2. Suit by Licensee. Licensee shall have the first right, but not the obligation, to take action in the prosecution, prevention, or
termination of any Infringement. Before Licensee commences an action with respect to any Infringement, Licensee shall consider in good faith the views of Harvard and potential effects on the public interest in making its decision whether to sue.
Should Licensee elect to bring suit against an infringer, Licensee shall keep Harvard reasonably informed of the progress of the action and shall give Harvard a reasonable opportunity in advance to consult with Licensee and offer its views about
major decisions affecting the litigation. Licensee shall give careful consideration to those views, but shall have the right to control the action; provided, however, that if Licensee fails to defend in good faith the validity and/or enforceability
of the Patent Rights in the action or, or if Licensee’s license to a Valid Claim in the suit terminates, Harvard may elect to take control of the action pursuant to Section 7.3. Should Licensee elect to bring suit against an infringer and
Harvard is joined as party plaintiff in any such suit, Harvard shall have the right to approve the counsel selected by Licensee to represent Licensee and Harvard, such approval not to be unreasonably withheld. The expenses of such suit or suits that
Licensee elects to bring, including any expenses of Harvard incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by Licensee and Licensee shall hold Harvard free, clear and harmless from
and against any and all costs of such litigation, including reasonable attorneys’ fees. Licensee shall not compromise or settle such litigation without the prior written consent of Harvard, which consent shall not be unreasonably withheld or
delayed. In the event Licensee exercises its right to sue pursuant to this Section 7.2, it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character,
including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then Harvard shall receive an amount equal to [***] and the remaining [***]
shall be retained by Licensee. 
 7.3. Suit by Harvard. If Licensee does not take action in the prosecution, prevention, or
termination of any Infringement pursuant to Section 7.2 above, and has not commenced negotiations with the infringer for the discontinuance of said Infringement, within ninety (90) days after receipt of notice to Licensee by Harvard
of the existence of an Infringement, Harvard may elect to do so. Should Harvard elect to bring suit against an infringer and Licensee is joined as party plaintiff in any such suit, Licensee shall have the right to approve the counsel selected by
Harvard to represent Harvard and Licensee, such approval not to be unreasonably withheld. The expenses of such suit or suits that Harvard elects to bring, including any expenses of Licensee incurred in conjunction with the prosecution of such suits
or the settlement thereof, shall be paid for entirely by Harvard and Harvard shall hold Licensee free, clear and harmless from and against any and all costs of such litigation, including reasonable attorneys’ fees. Harvard shall not compromise
or settle such litigation without the prior written consent of Licensee, which consent shall not be unreasonably withheld or delayed. In the event Harvard exercises its right to sue pursuant to this Section 7.3, it shall first reimburse itself
out of any sums recovered in such suit or 

  
 15 

 
in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such
reimbursement, any funds shall remain from said recovery, then Licensee shall receive an amount equal to [***] and the remaining [***] shall be retained by Harvard. 

7.4. Own Counsel. Each party shall always have the right to be represented by counsel of its own selection and at its own expense in
any suit instituted under this Article 7 by the other party for Infringement. 
 7.5. Cooperation. Each party agrees to cooperate
fully in any action under this Article 7 that is controlled by the other party, provided that the controlling party reimburses the cooperating party promptly for any costs and expenses incurred by the cooperating party in connection with providing
such assistance. 
 7.6. Declaratory Judgment. If a declaratory judgment action is brought naming Licensee and/or any of its
Affiliates or Sublicensees as a defendant and alleging invalidity or unenforceability of any claims within the Patent Rights, Licensee shall promptly notify Harvard in writing and, if such action is brought other than in connection with an
Infringement, Harvard may elect, upon written notice to Licensee within thirty (30) days after Harvard receives notice of the commencement of such action, to take over the sole defense of the invalidity and/or unenforceability aspect of the
action at its own expense. 
 7.7. No Initiation or Joinder by Harvard. Unless required by law or court order (on a jurisdiction-by-jurisdiction basis), Harvard shall not initiate or join infringement proceedings against Licensee, its Affiliates and Sublicensees in connection with
Licensee’s, its Affiliates’ or Sublicensees’ sale of Licensed Products or performance of Licensed Services outside of the Territory, the making, selling, using or performance of which are covered by the
Non-Exclusive Patent Rights related to Harvard Case No. [***]. Notwithstanding the foregoing, the parties agree that this Section 7.7 may be unenforceable under the laws of certain jurisdictions, and
in such case(s), the parties agree that it shall be deleted from the Agreement for such jurisdiction(s). 
  

	8.	 Warranties; Limitation of Liability. 

8.1. Compliance with Law and Harvard Representation. 

8.1.1. Licensee represents and warrants that it will comply, and will ensure that its Affiliates and Sublicensees comply, with all
local, state, federal and international laws and regulations relating to the development, manufacture, use, sale and importation of Licensed Products and performance of Licensed Services. Without limiting the foregoing, Licensee represents and
warrants that it will comply, and will ensure that its Affiliates and Sublicensees comply, with all United States export control laws and regulations. 

8.1.2. Harvard’s Office of Technology (“OTD”) represents, to the best of its knowledge as of the Effective Date and with
no further investigation, (a) Harvard is the assignee of the Patent Rights licensed hereunder; (b) Harvard has the right to enter in and to the Agreement; and (c) OTD has not granted rights in or to any Patent Rights that are
inconsistent with the rights granted to Licensee in this Agreement. 

  
 16 

 8.2. Disclaimer of Warranties. 

8.2.1. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO BE A WARRANTY BY HARVARD THAT IT CAN OR WILL BE ABLE TO OBTAIN PATENTS ON PATENT
APPLICATIONS INCLUDED IN THE PATENT RIGHTS, OR THAT ANY OF THE PATENT RIGHTS WILL AFFORD ADEQUATE OR COMMERCIALLY WORTHWHILE PROTECTION. 

8.2.2. HARVARD MAKES NO WARRANTIES WHATSOEVER AS TO THE COMMERCIAL OR SCIENTIFIC VALUE OF THE PATENT RIGHTS. HARVARD MAKES NO
REPRESENTATION THAT THE PRACTICE OF THE PATENT RIGHTS OR THE DEVELOPMENT, MANUFACTURE, USE, SALE OR IMPORTATION OF ANY LICENSED PRODUCT OR THE PRACTICE OF ANY LICENSED METHOD OR THE PERFORMANCE OF ANY LICENSED SERVICE, OR ANY ELEMENT THEREOF, WILL
NOT INFRINGE THE PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTY. 
 8.2.3. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT,
NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, PATENTS, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. 
 8.3. Limitation of Liability. 

8.3.1. Except with respect to matters for which Licensee is obligated to indemnify Harvard under Article 9, neither party will be
liable to the other with respect to any subject matter of this Agreement under any contract, negligence, strict liability or other legal or equitable theory for (a) any indirect, incidental, consequential or punitive damages or lost profits or
(b) cost of procurement of substitute goods, technology or services. 
 8.3.2. Harvard’s aggregate liability for all
damages of any kind arising out of or relating to this Agreement or its subject matter under any contract, negligence, strict liability or other legal or equitable theory shall not exceed the amounts paid to Harvard under this Agreement. 

 

	9.	 Indemnification and Insurance. 

9.1. Indemnity. 

9.1.1. Licensee shall indemnify, defend and hold harmless Harvard and its current and former directors, governing board members,
trustees, officers, faculty, medical and professional staff, employees, students, and agents and their respective successors, heirs and assigns (collectively, the “Indemnitees”) from and against any claim, liability, cost, expense, damage,
deficiency, loss or obligation of any kind or nature (including reasonable attorneys’ fees and other costs and expenses of litigation), based upon, arising out of, or otherwise relating to this Agreement or any Sublicense, including any cause
of action relating to product liability concerning any product, process, or service made, used, sold or performed pursuant to any right or license granted under this Agreement (collectively, “Claims”). Neither Licensee nor Harvard shall
settle any Claim without the prior written consent of the other, which consent shall not be unreasonably withheld. 

  
 17 

 9.1.2. Licensee shall, at its own expense, provide attorneys reasonably acceptable to
Harvard to defend against any actions brought or filed against any Indemnitee hereunder with respect to the subject of indemnity contained herein, whether or not such actions are rightfully brought. 

9.2. Insurance. 

9.2.1. Beginning at the time any Licensed Product is being commercially distributed or sold (other than for the purpose of obtaining
regulatory approvals) or any Licensed Service is being performed by Licensee, or by an Affiliate, Sublicensee or agent of Licensee, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts
not less than $5,000,000 per incident and $5,000,000 annual aggregate and naming the Indemnitees as additional insureds. Such commercial general liability insurance shall provide: (a) product liability coverage and (b) broad form
contractual liability coverage for Licensee’s indemnification obligations under this Agreement. 
 9.2.2. If Licensee elects to
self-insure all or part of the limits described above in Section 9.2.1 (including deductibles or retentions that are in excess of $250,000 annual aggregate) such self-insurance program must be acceptable to Harvard and CRICO/RMF (Harvard’s
insurer) in their sole discretion. The minimum amounts of insurance coverage required shall not be construed to create a limit of Licensee’s liability with respect to its indemnification obligations under this Agreement. 

9.2.3. Licensee shall provide Harvard with written evidence of such insurance upon request of Harvard. Licensee shall provide Harvard
with written notice at least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance. If Licensee does not obtain replacement insurance providing comparable coverage
within such fifteen (15) day period, Harvard shall have the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 

9.2.4. Licensee shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement
during: (a) the period that any Licensed Product is being commercially distributed or sold, or Licensed Services is being performed, by Licensee, or an Affiliate, Sublicensee or agent of Licensee; and (b) a reasonable period after the
period referred to in (a) above which in no event shall be less than fifteen (15) years. 
  

	10.	 Term and Termination. 

10.1. Term. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article
10, shall continue in full force and effect until the expiration of the last to expire Valid Claim (the “Term”). 

  
 18 

 10.2. Termination. 

10.2.1. Termination Without Cause. Licensee may terminate this Agreement upon sixty (60) days prior written notice to Harvard.

 10.2.2. Termination for Default. 

10.2.2.1. In the event that either party commits a material breach of its obligations under this Agreement and fails to cure that
breach within sixty (60) days after receiving written notice thereof, the other party may terminate this Agreement immediately upon written notice to the party in breach. 

10.2.2.2. If Licensee defaults in its obligations under Section 9.2 to procure and maintain insurance or, if Licensee has in any
event failed to comply with the notice requirements contained therein, then Harvard may terminate this Agreement immediately without notice or additional waiting period. 

10.2.2.3. Harvard shall be entitled to terminate this Agreement in accordance with the provisions of Section 3.4. 

10.2.2.4. Notwithstanding Sections 10.2.2.1 through 10.2.2.3 above, if Licensee disputes any alleged breach or default in good faith
by providing written notice to Harvard within thirty (30) days of receiving the notice of breach, Harvard shall not have the right to terminate this Agreement unless and until it has been determined in accordance with the arbitration mechanism
under this Section 10.2.2.4 that Licensee has committed the alleged breach entitling Harvard to terminate this Agreement, and Licensee fails to cure such breach within the applicable cure period after such determination. Any arbitration under
this Section 10.2.2.4 shall be held in Boston, MA under the then-current rules of the Judicial Arbitration and Mediation Services (JAMS) by one (1) arbitrator appointed in accordance with such rules or otherwise selected by the parties
upon mutual agreement (the -Arbitrator”). Within fifteen (15) days after the designation of the Arbitrator, the parties shall each simultaneously submit to the Arbitrator and to each
other a written statement of their respective positions on such disagreement. Each party shall have ten (10) days from receipt of the other party’s statement to submit a written response, which shall include any technical information in
support of such response. The Arbitrator shall have the right to meet with the parties, either alone or together, as necessary to make a determination. No later than sixty (60) days after the designation of the Arbitrator, the Arbitrator shall
render his/her decision, and provide the parties with a written statement setting forth the basis of the decision. Nothing in this Section 10.2.2.4 shall limit either party’s ability to pursue any other remedies legally available to
resolve the dispute. 
 10.2.3. Bankruptcy. Harvard may terminate this Agreement upon notice to Licensee if Licensee becomes
insolvent, is adjudged bankrupt, applies for judicial or extra-judicial settlement with its creditors, makes an assignment for the benefit of its creditors, voluntarily files for bankruptcy or has a receiver or trustee (or the like) in bankruptcy
appointed by reason of its insolvency, or in the event an involuntary bankruptcy action is filed against Licensee and not dismissed within ninety (90) days, or if Licensee becomes the subject of liquidation or dissolution proceedings or
otherwise discontinues business. 

  
 19 

 10.3. Effect of Termination. 

10.3.1. Termination of Rights. Upon expiration or termination of this Agreement by either party pursuant to any of the provisions of
Section 10.2: (a) the rights and licenses granted to Licensee under Article 2 shall terminate, all rights in and to and under the Patent Rights will revert to Harvard and neither Licensee nor its Affiliates may make any further use or
exploitation of the Patent Rights; and (b) any existing agreements that contain a Sublicense shall terminate to the extent of such Sublicense; provided, however, that, for each Sublicensee, upon termination of the Sublicense agreement with such
Sublicensee, if the Sublicensee is not then in breach of its Sublicense agreement with Licensee such that Licensee would have the right to terminate such Sublicense, such Sublicensee shall have the right to seek a license from Harvard. Harvard
agrees to negotiate such licenses in good faith under reasonable terms and conditions, which shall not impose any representations, warranties, obligations or liabilities on Harvard that are not included in this Agreement. 

10.3.2. Accruing Obligations. Termination or expiration of this Agreement shall not relieve the parties of obligations accruing prior
to such termination or expiration, including obligations to pay amounts accruing hereunder up to the date of termination or expiration. After the date of termination or expiration (except in the case of termination by Harvard pursuant to
Section 10.2), Licensee, its Affiliates and Sublicensees (a) may sell Licensed Products then in stock and (b) may complete the production of Licensed Products or performance of Licensed Service then in the process of production or
performance and sell the same; provided that, in the case of both (a) and (b), Licensee shall pay the applicable royalties and payments to Harvard in accordance with Article 4, provide reports and audit rights to Harvard pursuant to Article 5
and maintain insurance in accordance with the requirements of Section 9.2. 
 10.4. Survival. The parties’ respective
rights, obligations and duties under Articles 5, 9, 10 and 11 and Sections 8.2 and 8.3, as well as any rights, obligations and duties which by their nature extend beyond the expiration or termination of this Agreement, shall survive any expiration
or termination of this Agreement. In addition, Licensee’s obligations under Section 4.4 with respect to Sublicenses granted prior to expiration or termination of the Agreement shall survive such expiration or termination. 

 

	11.	 Miscellaneous. 

11.1. Preference for United States Industry. During the period of exclusivity of this license in the United States, Licensee shall
comply with 37 C.F.R. § 401.14 (i) or any successor rule or regulation. 
 11.2. No Security Interest. Licensee shall not enter
into any agreement under which Licensee grants to or otherwise creates in any third party a security interest in this Agreement or any of the rights granted to Licensee herein. Any grant or creation of a security interest purported or attempted to
be made in violation of the terms of this Section 11.2 shall be null and void and of no legal effect. 
 11.3. Use of Name.
Except as provided below, Licensee shall not, and shall ensure that its Affiliates and Sublicensees shall not, use or register the name “Harvard” (alone or as part of another name) or any logos, seals, insignia or other words, names,
symbols or devices that identify Harvard or any Harvard school, unit, division or affiliate (“Harvard Names”) for any purpose 

  
 20 

 
except with the prior written approval of, and in accordance with restrictions required by, Harvard. Without limiting the foregoing, Licensee shall, and shall ensure that its Affiliates and
Sublicensees shall, cease all use of Harvard Names on the termination or expiration of this Agreement except as otherwise approved by Harvard. This restriction shall not apply to any information required by law to be disclosed to any governmental
entity. 
 11.4. Entire Agreement. This Agreement is the sole agreement with respect to the subject matter hereof and except as
expressly set forth herein, supersedes all other agreements and understandings between the parties with respect to the same. 
 11.5.
Notices. Unless otherwise specifically provided, all notices required or permitted by this Agreement shall be in writing and may be delivered personally, or may be sent by facsimile, expedited delivery or certified mail, return receipt
requested, to the following addresses, unless the parties are subsequently notified of any change of address in accordance with this Section 11.5: 

If to Licensee         10X Technologies, Inc. 

7068 Koll Center Parkway 

Suite 401 

Pleasanton, CA 94566 

Attention: Serge Saxonov 

Email: serge@10xtechnologies.com 

Cc: Wilson Sonsini Goodrich and Rosati 

650 Page Mill Road 

Palo Alto, CA 94304-1050 

Attn: Vern Norviel 

Fax: 650-493-6811 

If to Harvard:         Office of Technology Development 

Harvard University 

Holyoke Center 727 

1350 Massachusetts Avenue 

Cambridge, Massachusetts 02138 

Facsimile: (617) 495-9568 

Attn.: Chief Technology Development Officer 

Any notice shall be deemed to have been received as follows: (a) by personal delivery or expedited delivery, upon receipt; (b) by
facsimile, one business day after transmission or dispatch; (c) by certified mail, as evidenced by the return receipt. If notice is sent by facsimile, a confirming copy of the same shall be sent by mail to the same address. 

11.6. Governing Law and Jurisdiction. This Agreement will be governed by, and construed in accordance with, the substantive laws of the
Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which the patent shall
have been granted. Any action, suit or other proceeding arising under or relating to this Agreement (a “Suit”) shall be brought in a court of competent jurisdiction in the 

  
 21 

 
Commonwealth of Massachusetts, and the parties hereby consent to the sole jurisdiction of the state and federal courts sitting in the Commonwealth of Massachusetts. Each party agrees not to raise
any objection at any time to the laying or maintaining of the venue of any Suit in any of the specified courts, irrevocably waives any claim that Suit has been brought in any inconvenient forum and further irrevocably waives the right to object,
with respect to any Suit, that such court does not have any jurisdiction over such party. 
 11.7. Binding Effect. This Agreement
shall be binding upon and inure to the benefit of the parties and their respective legal representatives, successors and permitted assigns. 

11.8. Headings. Section and subsection headings are inserted for convenience of reference only and do not form a part of this
Agreement. 
 11.9. Counterparts. The parties may execute this Agreement in two or more counterparts, each of which shall be deemed
an original. 
 11.10. Amendment; Waiver. This Agreement may be amended, modified, superseded or canceled, and any of the terms may
be waived, only by a written instrument executed by each party or, in the case of waiver, by the party waiving compliance. The delay or failure of either party at any time or times to require performance of any provisions hereof shall in no manner
affect the rights at a later time to enforce the same. No waiver by either party of any condition or of the breach of any term contained in this Agreement, whether by conduct, or otherwise, in any one or more instances, shall be deemed to be, or
considered as, a further or continuing waiver of any such condition or of the breach of such term or any other term of this Agreement. 

11.11. No Agency or Partnership. Nothing contained in this Agreement shall give either party the right to bind the other, or be deemed
to constitute either party as agent for or partner of the other or any third party. 
 11.12. Assignment and Successors; Assignment Fee.
This Agreement may not be assigned by either party without the consent of the other, and such consent will not be unreasonably withheld. Notwithstanding the foregoing, Licensee and/or its Affiliates will be entitled to assign and delegate all of
its rights and obligations under this Agreement without the consent of Harvard to (a) any of its Affiliates, (b) any non-Affiliate entity to which Licensee or its Affiliate sells or transfers all or
substantially all of its business or assets to which this Agreement pertains, or (c) a successor entity resulting from any merger, reincorporation, reorganization, or consolidation of Licensee or its Affiliate. Any assignment purported or
attempted to be made in violation of the terms of this Section 11.12 shall be null and void and of no legal effect. 
 11.13. Force
Majeure. Neither party will be responsible for delays resulting from causes beyond the reasonable control of such party, including fire, explosion, flood, war, strike, or riot, provided that the nonperforming party uses commercially reasonable
efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch whenever such causes are removed. 

  
 22 

 11.14. Interpretation. Each party hereto acknowledges and agrees that: (a) it
and/or its counsel reviewed and negotiated the terms and provisions of this Agreement and has contributed to its revision; (b) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be
employed in the interpretation of this Agreement; (c) the terms and provisions of this Agreement shall be construed fairly as to both parties hereto and not in favor of or against either party, regardless of which party was generally
responsible for the preparation of this Agreement; and (d) the use of “include,” “includes,” or “including” herein shall not be limiting and “or” shall not be exclusive. 

11.15. Severability. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent
jurisdiction or is deemed unenforceable, it is the intention of the parties that the remainder of this Agreement shall not be affected. 
 IN WITNESS
WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives as of the date first written above. 
  

									
	President and Fellows of Harvard College	 		 	10X Technologies, Inc.
					
	By:	 	/s/ Isaac T. Kohlberg	 		 	By:	 	/s/ Serge Saxonov
	Name:	 	Isaac T. Kohlberg	 		 	Name:	 	Serge Saxonov
		 	Senior Associate Provost	 		 	Title:	 	Chief Executive Officer
		 	Chief Technology Development Officer	 		 		 	
		 	Office of Technology Development	 		 		 	
	Title:	 	Harvard University	 		 		 	

  
 23 

 Exhibit 1.2 

[***] Patent Rights 
 [***] 

 Exhibit 1.3 

[***] Patent Rights 
 [***] 

 Exhibit 1.6 

Development Milestones 
 [***] 

 Exhibit 1.7 

Development Plan 
 [***] 

 Exhibit 1.8 

Exclusive Patent Rights 
 [***] 

 Exhibit 1.14 

Non-Exclusive Patent Rights 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]